Meeting Banner
Abstract #0172

Antibiotic rifaximin for treatment of chronic liver disease-induced HE: a longitudinal in vivo 1H-MRS study of brain metabolism

Emmanuelle Flatt1, Cristina Cudalbu2, Olivier Braissant3, Stefanita Mitrea2, Dario Sessa4, Valérie A. McLin4, and Rolf Grütter1

1LIFMET, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, 2CIBM, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, 3Service of Biomedecine, University Hospital of Lausanne, Lausanne, Switzerland, 4Swiss Center for Liver Disease in Children, Department of Pediatrics, University Hospitals Geneva, Geneva, Switzerland

Rifaximin is a commonly-used antibiotic to treat hepatic encephalopathy(HE), a complex neuropsychiatric syndrome caused by hepatic dysfunction. Rifaximin reduces the production of gut ammonia, the main toxin in HE pathogenesis. We hypothesized that the effect of rifaximin on neurometabolic profile is dose-related. Therefore, in this study, the effects of rifaximin administered at 6x human-dose were assessed, in vivo and longitudinally on brain metabolites in bile-duct ligated(BDL) rats using 1H-MRS at 9.4T, biochemical and behavioral tests. They were compared with non-treated and human-dose treated rats. We showed that higher-dose rifaximin treatment was associated with positive effects on brain Gln,Glu and osmoregulation.

This abstract and the presentation materials are available to members only; a login is required.

Join Here